| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.05. | TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing | 88 | GlobeNewswire (Europe) | FORT WORTH, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the "Company" or "TFF Pharmaceuticals"), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 17.05. | TFF Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | TFF Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary | 1 | Reuters | ||
| 01.05. | TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering | 2 | GlobeNewswire (USA) | ||
| 30.04. | TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 29.04. | TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting | 111 | GlobeNewswire (Europe) | Data Now Available on Company Website Following 8-K Filing Data Demonstrate that Treatment with TFF TAC Prevents Lung Transplant Rejection at Only One-sixth of the Dose of Oral Tacrolimus and at Two-thirds... ► Artikel lesen | |
| 29.04. | TFF Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.04. | TFF Pharmaceuticals, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 18.04. | TFF Pharmaceuticals, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 08.04. | TFF Pharmaceuticals, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 28.03. | TFF Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
| 28.03. | TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results | 644 | GlobeNewswire (Europe) | FORT WORTH, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| 27.03. | TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs | 59 | GlobeNewswire (Europe) | Eight of Eight Patients Successfully Transitioned from Oral Tacrolimus to TFF TAC with No Sign of Acute Rejection at Reduced Systemic Exposures Data from TFF VORI Phase 2 and EAP Program Continue... ► Artikel lesen | |
| 22.03. | TFF Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.03. | TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | 1 | GlobeNewswire (USA) | ||
| 20.03. | TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Announces Update on Clinical Programs | 114 | GlobeNewswire (Europe) | Company to Prioritize Clinical Development of Tacrolimus Inhalation Powder (TFF TAC) based on Positive Phase 2 Data, the Potential to Address a Significant Unmet Need in Lung Transplant Medicine and... ► Artikel lesen | |
| 14.03. | TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference - March 17-19, 2024 | 1 | GlobeNewswire (USA) | ||
| 24.01. | TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference | 3 | GlobeNewswire (USA) | ||
| 19.12.23 | TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC | 562 | GlobeNewswire (Europe) | Treatment with TFF VORI resulted in positive treatment outcomes based on clinical, mycologic and radiologic responses while maintaining a favorable safety/tolerability profile, with no all-cause mortality... ► Artikel lesen | |
| 18.12.23 | TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TAC | 4 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| TUI | 3.891 |
| NVIDIA | 2.727 |
| GAMESTOP | 2.181 |
| NEL | 1.955 |
| BAYER | 1.762 |
| EVOTEC | 1.653 |
| PLUG POWER | 1.637 |
| BYD | 1.155 |
| SUPER MICRO COMPUTER | 787 |
| VOLKSWAGEN | 777 |
| DEUTSCHE LUFTHANSA | 699 |
| RHEINMETALL | 694 |
| BIONTECH | 640 |
| AIXTRON SE | 608 |
| ALLIANZ | 504 |
| DEUTSCHE TELEKOM | 502 |
| BASF | 500 |
| PALANTIR TECHNOLOGIES | 498 |
| OMV | 492 |
| TESLA | 490 |
| THYSSENKRUPP | 488 |
| DEUTSCHE BANK | 482 |
| NOVAVAX | 482 |
| SIEMENS ENERGY | 464 |
| RWE | 453 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
